Today: 2 May 2026
Browse Category

NASDAQ:NRXP 14 January 2026

NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

NRx Pharmaceuticals shares fell 4.3% to $2.13 in premarket trading after the FDA granted Fast Track status to its ketamine-based NRX-100 for suicidal ideation. The company plans to submit data from over 70,000 U.S. patients to support accelerated approval. Investors await further FDA feedback and updates during the San Francisco healthcare conference.
14 January 2026
··

Stock Market Today

  • Guardant Health Stock Analysis: Attractive Valuation Amid Mixed Price Moves
    May 2, 2026, 12:25 PM EDT. Guardant Health (GH) trades near US$87.60, down 1.5% last week and 3.9% over a month, yet up 87% in the past year. Despite a 35.3% drop over five years, its multi-year gains reflect strong market interest in its healthcare diagnostics technology. A Discounted Cash Flow (DCF) model estimates GH's intrinsic value at approximately US$173.89 per share, suggesting it is undervalued by nearly 50%. This model projects free cash flow turning positive by 2030, highlighting long-term growth potential. Given negative current free cash flow, Price-to-Sales (P/S) ratios are used as alternative valuation metrics. Guardant Health's valuation score of 3 out of 6 indicates moderate potential, balancing recent pullbacks against solid longer-term returns and prospects.

Latest article

Workday Inc. Sets May 21 Earnings Date: Why Its AI Bet Faces a Crucial Test

Workday Inc. Sets May 21 Earnings Date: Why Its AI Bet Faces a Crucial Test

2 May 2026
Workday will report fiscal 2027 first-quarter results after markets close on May 21. The company previously forecast first-quarter subscription revenue of $2.335 billion, up 13%. Shares closed Friday at $126.96, up 3.73%, amid ongoing pressure from AI competition and investor concerns over growth. CEO Aneel Bhusri returned in February as the firm pushes new AI-driven products.
Clorox Stock Sinks After Outlook Cut: Why the Bleach Maker’s Profit Squeeze Isn’t Over

Clorox Stock Sinks After Outlook Cut: Why the Bleach Maker’s Profit Squeeze Isn’t Over

2 May 2026
Clorox lowered its fiscal 2026 adjusted earnings forecast to $5.45–$5.65 per share, down from $5.95–$6.30, citing higher costs and slower recovery in some categories. Shares dropped 9.7% to $87.11 Friday. Net sales for the third quarter were $1.67 billion, nearly flat year-over-year. The GOJO acquisition is expected to dilute adjusted earnings by 2 to 4 cents per share.
Go toTop